source
- STAT+: Next-gen Duchenne drug from Entrada disappointsA next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.STAT · 3mo ago↗ source
- Angelini fortifies neurology portfolio with $4.1B buyout of CatalystAngelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s po…Endpoints · 3mo ago↗ source
- STAT+: Color me skeptical: Drinking gold is not an ALS cureIn this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.STAT · 3mo ago